X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs SUN PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER SUN PHARMA PFIZER/
SUN PHARMA
 
P/E (TTM) x 24.2 15.3 157.9% View Chart
P/BV x 3.8 3.6 106.8% View Chart
Dividend Yield % 0.8 0.2 396.0%  

Financials

 PFIZER   SUN PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-16
SUN PHARMA
Mar-16
PFIZER/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7241,201 226.9%   
Low Rs1,611706 228.1%   
Sales per share (Unadj.) Rs440.9117.5 375.3%  
Earnings per share (Unadj.) Rs48.719.6 248.5%  
Cash flow per share (Unadj.) Rs75.823.8 318.3%  
Dividends per share (Unadj.) Rs15.001.00 1,500.0%  
Dividend yield (eoy) %0.70.1 659.9%  
Book value per share (Unadj.) Rs462.9130.5 354.8%  
Shares outstanding (eoy) m45.752,406.60 1.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.98.1 60.6%   
Avg P/E ratio x44.548.7 91.5%  
P/CF ratio (eoy) x28.640.1 71.4%  
Price / Book Value ratio x4.77.3 64.1%  
Dividend payout %30.85.1 603.6%   
Avg Mkt Cap Rs m99,1632,294,813 4.3%   
No. of employees `0002.914.7 19.6%   
Total wages/salary Rs m2,75847,971 5.7%   
Avg. sales/employee Rs Th6,981.719,169.8 36.4%   
Avg. wages/employee Rs Th954.53,253.0 29.3%   
Avg. net profit/employee Rs Th771.13,197.9 24.1%   
INCOME DATA
Net Sales Rs m20,170282,697 7.1%  
Other income Rs m8576,170 13.9%   
Total revenues Rs m21,028288,867 7.3%   
Gross profit Rs m4,31083,239 5.2%  
Depreciation Rs m1,23910,135 12.2%   
Interest Rs m54,769 0.1%   
Profit before tax Rs m3,92374,505 5.3%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m99-6,852 -1.4%   
Tax Rs m1,7949,349 19.2%   
Profit after tax Rs m2,22847,159 4.7%  
Gross profit margin %21.429.4 72.6%  
Effective tax rate %45.712.5 364.5%   
Net profit margin %11.016.7 66.2%  
BALANCE SHEET DATA
Current assets Rs m16,299308,646 5.3%   
Current liabilities Rs m7,594132,477 5.7%   
Net working cap to sales %43.262.3 69.3%  
Current ratio x2.12.3 92.1%  
Inventory Days Days6583 78.7%  
Debtors Days Days2688 29.3%  
Net fixed assets Rs m8,622133,606 6.5%   
Share capital Rs m4582,407 19.0%   
"Free" reserves Rs m20,722266,909 7.8%   
Net worth Rs m21,180314,042 6.7%   
Long term debt Rs m2531,167 0.1%   
Total assets Rs m29,137542,196 5.4%  
Interest coverage x755.516.6 4,544.8%   
Debt to equity ratio x00.1 1.2%  
Sales to assets ratio x0.70.5 132.8%   
Return on assets %7.79.6 80.0%  
Return on equity %10.515.0 70.0%  
Return on capital %19.017.8 107.0%  
Exports to sales %0.114.0 0.4%   
Imports to sales %17.53.1 556.3%   
Exports (fob) Rs m1239,572 0.0%   
Imports (cif) Rs m3,5268,882 39.7%   
Fx inflow Rs m5242,171 0.1%   
Fx outflow Rs m14021,583 0.6%   
Net fx Rs m-8820,588 -0.4%   
CASH FLOW
From Operations Rs m3,43667,694 5.1%  
From Investments Rs m-6,991-44,549 15.7%  
From Financial Activity Rs m-619-19,243 3.2%  
Net Cashflow Rs m-4,1743,902 -107.0%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 5.1 146.2%  
FIIs % 4.9 23.0 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 8.3 285.5%  
Shareholders   85,207 133,026 64.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  CADILA HEALTHCARE  ALEMBIC LTD  

Compare PFIZER With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 18, 2017 (Close)

TRACK PFIZER

PFIZER - GLENMARK PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS